CMS-D001 is named as a drug or biological intervention in 2 clinical trials in our China trial register, none of which are currently recruiting. The lead sponsor is Dermavon Holdings Limited. Registered phases: Phase 2 and Phase 2/3. Conditions studied include Moderate to Severe Atopic Dermatitis; Moderate to Severe Plaque Psoriasis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07432854 | A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis (ClinicalTrials.gov ↗) Moderate to Severe Plaque Psoriasis |
Phase 2/3 | Not yet open |
| NCT07465120 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis (ClinicalTrials.gov ↗) Moderate to Severe Atopic Dermatitis |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Moderate to Severe Atopic Dermatitis | 1 |
| Moderate to Severe Plaque Psoriasis | 1 |
| Lead sponsor | Trials |
|---|---|
| Dermavon Holdings Limited | 2 |
| Register | CMS-D001 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CMS-D001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CMS-D001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.